Psychiatry and Neurology, Neurology · Bend, OR
NPI
1447549183
Since 2011
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
2349 NE Conners Ave
Bend, OR, 97701
Phone (541) 317-0044
Groups this clinician bills Medicare through
Medicare paid, 2024
$308K
38,502 services
Medicare patients, 2024
483
Average age 74
Drug cost, 2024
$1.5M
5,440 prescriptions
Company payments, 2025
$156
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tyler A Clark was code J0585 (injection, onabotulinumtoxina, 1 unit), 30,808 times for 67 patients. In total Tyler A Clark billed 38,502 services in 42 codes, and Medicare paid $308K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 30,808 | 67 | $4.98 | $154K |
| A9585 Injection, gadobutrol, 0.1 ml | Office | 2,550 | 30 | $0.25 | $641 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 670 | 385 | $11.65 | $7,806 |
| 99213 Office E&M - Established | Office | 544 | 346 | $61.31 | $33K |
| 99214 Office E&M - Established | Office | 174 | 134 | $86.22 | $15K |
| 99212 Office E&M - Established | Office | 108 | 64 | $38.78 | $4,188 |
| 64616 Musculoskeletal | Office | 92 | 30 | $131.76 | $12K |
| 99204 Office E&M - New | Office | 64 | 64 | $120.40 | $7,706 |
| 99215 Office E&M - Established | Office | 52 | 45 | $126.31 | $6,568 |
| 99203 Office E&M - New | Office | 47 | 47 | $69.97 | $3,289 |
| 95983 Electrical Nerve Conductivity | Office | 36 | 17 | $35.70 | $1,285 |
| 95970 Electrical Nerve Conductivity | Office | 36 | 21 | $12.68 | $456 |
| 95874 Musculoskeletal | Office | 34 | 14 | $58.65 | $1,994 |
| 64612 Musculoskeletal | Office | 33 | 12 | $140.92 | $4,651 |
| 70551 MRI/MRA - Head and Neck | Office | 32 | 32 | $149.03 | $4,769 |
By year: 2022 $192K for 18,788 services; 2023 $247K for 29,082 services; 2024 $308K for 38,502 services.
Medicare prescription drug claims, 2024
In 2024, the drug Tyler A Clark prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 948 prescriptions and refills. In total Tyler A Clark wrote 5,440 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 948 | 1,700 | 226 | $27K |
| Gabapentin Generic | 510 | 833 | 117 | $7,113 |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 510 | 867 | 116 | $38K |
| Donepezil Hcl Generic | 312 | 573 | 84 | $3,010 |
| Memantine Hcl Generic | 178 | 254 | 41 | $5,478 |
| Duloxetine Hcl Generic | 168 | 262 | 34 | $3,273 |
| Amantadine Amantadine Hcl | 156 | 238 | 40 | $8,656 |
| Sertraline Hcl Generic | 156 | 246 | 39 | $2,193 |
| Fludrocortisone Acetate Generic | 139 | 204 | 39 | $2,892 |
| Rytary Carbidopa/Levodopa | 128 | 235 | 26 | $179K |
| Pregabalin Generic | 115 | 150 | 24 | $3,978 |
| Primidone Generic | 110 | 184 | 27 | $1,765 |
| Trazodone Hcl Generic | 110 | 171 | 35 | $689 |
| Atorvastatin Calcium Generic | 87 | 131 | 21 | $1,054 |
| Propranolol Hcl Generic | 84 | 142 | 22 | $1,193 |
Brand drugs: - claims; generic drugs: 5,008 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tyler A Clark $156 ($156 in general payments such as food, travel and fees) from 1 company. The largest payer was Abbott Laboratories with $156.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 10 | $156 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.